Literature DB >> 14724894

The value of risk-free cigarettes--do smokers underestimate the risk?

Henrik Hammar1, Olof Johansson-Stenman.   

Abstract

The health risk of smoking is valued using the contingent valuation method, applied to a Swedish sample of smokers. The respondents were asked to put a value on newly developed cigarettes with no associated health risks. The average additional willingness to pay for the new cigarettes is estimated to be between 10 and 41 SEK per pack, where the variation is due to statistical method, discounting, and whether the open-ended or closed-ended question format is used. Using medical data on life shortening effects of smoking, the results indicate rather low values put on a lost life-year, compared to most existing estimates based on other methods. This may indicate that smokers do underestimate the health risk of smoking. There is also initial optimism-bias regarding people's own ability to quit smoking at will. However, there are remaining methodological questions and we found little or no sensitivity to scope. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 14724894     DOI: 10.1002/hec.794

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  4 in total

1.  Willingness-to-pay and demand curves: a comparison of results obtained using different elicitation formats.

Authors:  David K Whynes; Emma J Frew; Jane L Wolstenholme
Journal:  Int J Health Care Finance Econ       Date:  2005-12

2.  A Cross-sectional Examination of What Smokers Perceive to be Important and Their Willingness to Pay for Tobacco Cessation Medications.

Authors:  Shanta R Dube; Michael F Pesko; Xin Xu
Journal:  J Public Health Manag Pract       Date:  2016 Jan-Feb

3.  Customers' preferences and willingness to pay for a future dengue vaccination: a study of the empirical evidence in Vietnam.

Authors:  Trung Quang Vo; Quang Vinh Tran; Nam Xuan Vo
Journal:  Patient Prefer Adherence       Date:  2018-11-27       Impact factor: 2.711

4.  Scope Issue in Contingent Valuation Studies of the COVID-19 Vaccine: The Case of China.

Authors:  Jianhong Xiao; Yihui Wu; Min Wang; Zegang Ma
Journal:  Appl Health Econ Health Policy       Date:  2022-01-10       Impact factor: 3.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.